1-(5-Methyl-2-phenyl-1,3-thiazol-4-yl)ethan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(5-Methyl-2-phenyl-1,3-thiazol-4-yl)ethan-1-one
• 英文别名: 1-(5-methyl-2-phenyl-1,3-thiazol-4-yl)ethanone
• 化学式: C₁₂H₁₁NOS
• mdl: MFCD01911449
• 分子量: 217.29
• InChiKey: FEUZABIFMROQRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(5-Methyl-2-phenyl-1,3-thiazol-4-yl)ethan-1-one 、 四氯化钛 生成 5-methyl-4-[(Z)-3-(5-methyl-2-phenyl-1,3-thiazol-4-yl)but-2-en-2-yl]-2-phenyl-1,3-thiazole
  参考文献：
  名称：

  TOMOTA, AKIXIKO;KANEHKO, AKIRA;ISIDZUKA, MITSUO SUDZUKI XISAO

  摘要：

  DOI：
• 作为产物：
  描述：

  4-chloro-pentane-2,3-dione 、 硫代苯甲酰胺 生成 1-(5-Methyl-2-phenyl-1,3-thiazol-4-yl)ethan-1-one
  参考文献：
  名称：

  TOMOTA, AKIXIKO;KANEHKO, AKIRA;ISIDZUKA, MITSUO SUDZUKI XISAO

  摘要：

  DOI：

文献信息

• THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS
  申请人：Oalmann Christopher

  公开号：US20110306609A1

  公开（公告）日：2011-12-15

  Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了结构式（Ia）的新型Sirtuin调节化合物及其使用方法。这些Sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块性疾病，炎症，癌症和/或潮红，以及从中受益的疾病或疾病增加线粒体活性。还提供了包含Sirtuin调节化合物与另一种治疗剂组合的组合物。
• TOMOTA, AKIXIKO;KANEHKO, AKIRA;ISIDZUKA, MITSUO
  作者：TOMOTA, AKIXIKO、KANEHKO, AKIRA、ISIDZUKA, MITSUO

  DOI：——

  日期：——
• Method for Augmenting B Cell Depletion
  申请人：Chan C. Andrew

  公开号：US20080075719A1

  公开（公告）日：2008-03-27

  The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods of treating B cell disorders by this approach is also provided.
• TYROSINE DERIVATIVE
  申请人：Jackson David Y.

  公开号：US20090325962A1

  公开（公告）日：2009-12-31

  The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
• US8343997B2
  申请人：——

  公开号：US8343997B2

  公开（公告）日：2013-01-01